These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 9458979)
1. Growth medium effect on the antifungal activity of LY 303366. Klepser ME; Ernst EJ; Ernst ME; Pfaller MA Diagn Microbiol Infect Dis; 1997 Dec; 29(4):227-31. PubMed ID: 9458979 [TBL] [Abstract][Full Text] [Related]
2. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Ernst ME; Klepser ME; Wolfe EJ; Pfaller MA Diagn Microbiol Infect Dis; 1996; 26(3-4):125-31. PubMed ID: 9078447 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Moore CB; Oakley KL; Denning DW Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of endpoints for antifungal susceptibility determinations with LY303366. Klepser ME; Ernst EJ; Ernst ME; Messer SA; Pfaller MA Antimicrob Agents Chemother; 1998 Jun; 42(6):1387-91. PubMed ID: 9624481 [TBL] [Abstract][Full Text] [Related]
5. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species. Karlowsky JA; Harding GA; Zelenitsky SA; Hoban DJ; Kabani A; Balko TV; Turik M; Zhanel GG Antimicrob Agents Chemother; 1997 Nov; 41(11):2576-8. PubMed ID: 9371373 [TBL] [Abstract][Full Text] [Related]
6. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Ernst EJ; Roling EE; Petzold CR; Keele DJ; Klepser ME Antimicrob Agents Chemother; 2002 Dec; 46(12):3846-53. PubMed ID: 12435687 [TBL] [Abstract][Full Text] [Related]
8. [The fungicidal activity and paradoxical effect of caspofungin against yeast. Influence of culture medium and incubation time]. Cantón E; Pemán J; Romero M; Valentín A; Gobernado M Rev Esp Quimioter; 2007 Dec; 20(4):433-41. PubMed ID: 18563217 [TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Ernst EJ; Klepser ME; Ernst ME; Messer SA; Pfaller MA Diagn Microbiol Infect Dis; 1999 Feb; 33(2):75-80. PubMed ID: 10091029 [TBL] [Abstract][Full Text] [Related]
11. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464 [TBL] [Abstract][Full Text] [Related]
12. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561 [TBL] [Abstract][Full Text] [Related]
13. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Pai MP; Jones AL; Mullen CK Diagn Microbiol Infect Dis; 2007 May; 58(1):129-32. PubMed ID: 17240112 [TBL] [Abstract][Full Text] [Related]
14. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3. Varga I; Sóczó G; Kardos G; Majoros L J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178 [TBL] [Abstract][Full Text] [Related]
16. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Chamilos G; Lewis RE; Albert N; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Jun; 51(6):2257-9. PubMed ID: 17438060 [TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. Mikamo H; Sato Y; Tamaya T J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180 [TBL] [Abstract][Full Text] [Related]
18. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp. Hall D; Bonifas R; Stapert L; Thwaites M; Shinabarger DL; Pillar CM Diagn Microbiol Infect Dis; 2017 Nov; 89(3):205-211. PubMed ID: 28826987 [TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Espinel-Ingroff A Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349 [TBL] [Abstract][Full Text] [Related]
20. Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Locke JB; Almaguer AL; Donatelli JL; Bartizal KF Infect Dis Obstet Gynecol; 2018; 2018():7040498. PubMed ID: 29681727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]